Tungray Technologies Inc Announcement: If You Have Suffered Losses in Tungray Technologies Inc (NASDAQ: TRSG), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Crocs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CROX
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Crocs,
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Newmont Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NEM
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Newmont Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NEM
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action
ROSEN, A LONGSTANDING LAW FIRM, Encourages Target Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – TGT
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2